List of Excipients in Branded Drug LOPERAMIDE HYDROCHLORIDE, SIMETHICONE

« Back to Dashboard

Generic Drugs Containing LOPERAMIDE HYDROCHLORIDE, SIMETHICONE

Company	Ingredient	NDC	Excipient
Guardian Drug Company	loperamide hydrochloride, simethicone	53041-263	ACESULFAME POTASSIUM
Guardian Drug Company	loperamide hydrochloride, simethicone	53041-263	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Guardian Drug Company	loperamide hydrochloride, simethicone	53041-263	CELLULOSE, MICROCRYSTALLINE
Guardian Drug Company	loperamide hydrochloride, simethicone	53041-263	CROSCARMELLOSE SODIUM
Guardian Drug Company	loperamide hydrochloride, simethicone	53041-263	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in LOPERAMIDE HYDROCHLORIDE, SIMETHICONE?

# Of NDCs	Excipient
1	ACESULFAME POTASSIUM
1	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	SILICON DIOXIDE

Loperamide Hydrochloride and Simethicone Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 11, 2026

Loperamide hydrochloride plus simethicone is a mature over-the-counter combination for diarrhea accompanied by gas-related discomfort. The principal marketed U.S. reference product is Imodium Multi-Symptom Relief, containing loperamide hydrochloride 2 mg and simethicone 125 mg per caplet. The active ingredients are old, inexpensive, and broadly available. Commercial differentiation therefore depends on dosage-form performance, excipient selection, manufacturing efficiency, packaging, regulatory positioning, and consumer convenience rather than core active-ingredient exclusivity.

The strongest opportunities are fast-disintegrating tablets, swallowability improvements, child-resistant and senior-friendly packaging, lower-cost generic manufacture, private-label supply, and geographically adapted products. The main risks are monograph compliance, dose-related misuse of loperamide, product-quality requirements for simethicone dispersion, and limited ability to secure broad composition-of-matter protection.

What drugs and indications does loperamide hydrochloride plus simethicone cover?

The combination treats acute diarrhea and associated symptoms of abdominal bloating, pressure, or discomfort caused by excess gas. Loperamide reduces intestinal motility and secretion. Simethicone reduces surface tension at the gas-liquid interface and facilitates coalescence and passage of gas.

Parameter	Loperamide hydrochloride	Simethicone
Typical combination strength	2 mg	125 mg
Primary role	Antidiarrheal	Antiflatulent
U.S. status	OTC drug	OTC drug
Common dosage form	Caplet, tablet, capsule	Tablet, chewable, softgel, suspension
Core commercial rationale	Controls diarrhea	Addresses gas discomfort
Key safety issue	Misuse at excessive doses can cause serious cardiac events	Generally low systemic absorption

The U.S. Drug Facts labeling for the combination directs adults and children 12 years and older to take two caplets initially, followed by one caplet after each loose stool, subject to the labeled daily maximum. The product is not intended for children under 6 years without professional direction, and the label contains warnings regarding bloody or black stools, fever, prolonged symptoms, and excessive use. [1]

What excipients are used in loperamide-simethicone products?

The excipient system depends on the dosage form and manufacturer. Immediate-release caplets commonly use a combination of fillers, binders, disintegrants, glidants, lubricants, coating polymers, pigments, and polishing agents.

Representative excipient classes include:

Excipient function	Common candidates	Commercial purpose
Diluent	Microcrystalline cellulose, dibasic calcium phosphate, starch	Controls tablet mass and compression
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Croscarmellose sodium, sodium starch glycolate	Promotes rapid breakup after swallowing
Glidant	Colloidal silicon dioxide, talc	Improves powder flow
Lubricant	Magnesium stearate, stearic acid	Reduces sticking and ejection force
Film coating	Hypromellose, polyethylene glycol, titanium dioxide	Improves appearance, handling, and swallowability
Colorant	Aluminum lakes and approved pigments	Product identification and branding
Simethicone carrier	Powdered simethicone, colloidal silica, carbohydrate or mineral carrier	Enables uniform distribution of a hydrophobic active

The inactive ingredients listed in marketed caplets may include microcrystalline cellulose, calcium phosphate, starch, croscarmellose sodium, sodium starch glycolate, povidone, colloidal silicon dioxide, magnesium stearate, talc, hypromellose, polyethylene glycol, titanium dioxide, and colorants. Exact composition must be verified against the applicable manufacturer label because generic and private-label products may use materially different excipient systems. [2]

Why is simethicone technically difficult in a compressed tablet?

Simethicone is hydrophobic and may be supplied as a dispersion or adsorbed powder. Uniformity can be difficult when a low-dose loperamide component is combined with a much larger simethicone load. The formulation must control:

• Simethicone distribution across the blend.
• Segregation during transfer and compression.
• Tablet friability and capping.
• Dissolution and disintegration behavior.
• Assay and content uniformity of loperamide.
• Stability under heat and humidity.
• Interaction between coating materials and the simethicone phase.

A high-shear granulation process may improve blend uniformity but can create scale-up and moisture-control issues. Direct compression can reduce manufacturing steps but requires excipients with consistent flow, compactibility, and particle-size distribution.

What excipient strategy best supports a generic caplet?

A cost-focused generic strategy should use a conventional immediate-release platform with robust content uniformity and a short manufacturing process. A practical target is a directly compressible blend or a dry-granulated system using microcrystalline cellulose, dibasic calcium phosphate, a superdisintegrant, colloidal silicon dioxide, and magnesium stearate.

The main formulation objectives are:

1. Maintain rapid disintegration without excessive friability.
2. Prevent simethicone segregation during blending and transfer.
3. Achieve reliable loperamide content uniformity despite the low 2 mg dose.
4. Avoid unnecessary excipients that increase cost or regulatory complexity.
5. Match the reference product’s appearance and handling closely enough to support substitution and consumer acceptance.

A formulation developer should not assume that the lowest excipient count is optimal. A small increase in binder or glidant may reduce rejected batches, tablet-weight variation, and compression downtime. The commercial value comes from total cost per saleable unit, not simply raw-material cost.

Which dosage forms offer the strongest commercial opportunities?

Immediate-release caplets

Caplets are the lowest-risk entry platform. They support existing consumer expectations, conventional packaging, and standard quality testing. The main opportunity is manufacturing cost reduction or private-label supply.

Chewable tablets

Chewable products can improve access for consumers who have difficulty swallowing. They also create scope for flavor, texture, and sugar-free positioning. The technical challenge is masking loperamide’s taste while preserving acceptable simethicone dispersion and tablet hardness.

Potential excipient tools include mannitol, sorbitol, xylitol, crospovidone, flavor systems, high-intensity sweeteners, and taste-masking polymers. Polyols can increase hygroscopicity and may affect gastrointestinal tolerance, so moisture-barrier packaging is important.

Orally disintegrating tablets

An orally disintegrating formulation could target portability and swallowability. The 2 mg loperamide dose is compatible with low-mass ODT design, but the 125 mg simethicone load makes tablet size, mouthfeel, and uniform dispersion more difficult. An ODT may require porous excipient architecture, specialized compression, or a multiparticulate approach.

Softgels and liquid-filled capsules

Softgels are suitable for simethicone but are less straightforward for a combined loperamide-simethicone product. They require compatible fill formulations, shell manufacturing, and more complex stability controls. Their commercial advantage would be strongest where consumers associate softgels with easier swallowing or premium quality.

Oral suspensions

Suspensions can serve pediatric or swallowing-impaired populations, but loperamide labeling and pediatric safety restrictions materially limit the addressable market. Simethicone suspension systems also require control of sedimentation, redispersibility, viscosity, and dose uniformity. This is a specialized opportunity rather than the default generic platform.

What patents protect loperamide hydrochloride and simethicone products?

The active ingredients are not protected by current composition-of-matter patents in the United States. Loperamide was disclosed in early Janssen patent literature, including U.S. Patent No. 3,714,159, which expired long ago. Simethicone is an established mixture of polydimethylsiloxane and silicon dioxide and has no meaningful modern molecule-level exclusivity for this combination. [3]

Potentially relevant protection may instead concern:

• Specific tablet compositions.
• Taste-masking systems.
• ODT or chewable architectures.
• Multiparticulate delivery.
• Packaging and dosing systems.
• Manufacturing processes.
• Combination claims with narrow excipient ratios.

Such patents must be assessed claim by claim. A patent covering a narrow excipient percentage range may not block a conventional generic using a different filler, binder, or granulation method.

When does loperamide-simethicone lose exclusivity?

The product has no meaningful remaining U.S. exclusivity period based on the active ingredients. It is a mature OTC combination sold through branded, generic, store-brand, and international channels.

Exclusivity category	Current relevance
New chemical entity exclusivity	None
Composition-of-matter patent	Expired or unavailable for the active ingredients
Pediatric exclusivity	No material current exclusivity identified
Orphan exclusivity	Not applicable
Biologic exclusivity	Not applicable
OTC monograph exclusivity	No conventional branded exclusivity period
Trademark protection	Relevant to branded products
Formulation patents	Potentially relevant only if valid and claim scope is meaningful

The commercial moat is therefore primarily brand recognition, distribution, shelf placement, regulatory execution, and manufacturing economics.

What is the FDA regulatory and Orange Book status?

Loperamide hydrochloride and simethicone are marketed as OTC ingredients under FDA nonprescription drug requirements. The product labeling identifies active ingredients, uses, warnings, directions, and inactive ingredients under the Drug Facts framework. [1]

The combination is generally approached as an OTC product rather than as a conventional prescription product with a patent-based Orange Book strategy. The Orange Book is principally relevant to approved prescription and certain approved nonprescription drug products submitted through the NDA pathway. A monograph-compliant OTC product does not ordinarily rely on listed Orange Book patents to create market exclusivity. [4]

A manufacturer entering this market must establish:

• Compliance with the applicable OTC monograph or another lawful FDA pathway.
• Conformity with current labeling requirements.
• Drug establishment registration and product listing.
• Current good manufacturing practice compliance.
• Finished-product identity, strength, quality, purity, and stability.
• Appropriate controls for content uniformity and dose delivery.

A formulation that uses novel excipients, unusual delivery technology, or claims outside the monograph framework may require a separate FDA review pathway.

Which companies are challenging the reference product?

Competition is primarily commercial rather than Paragraph IV litigation. Relevant competitors include:

• Kenvue and its Imodium brand portfolio.
• Perrigo and other private-label manufacturers.
• Major retail pharmacy and mass-merchandiser store brands.
• Contract manufacturers supplying generic and retailer products.
• International consumer-health companies marketing loperamide or simethicone combinations under local brands.

A conventional OTC generic launch does not require the same litigation posture as a prescription abbreviated new drug application. Paragraph IV certification is therefore not the central market-entry mechanism for most products in this category. A Paragraph IV dispute could arise if a product is tied to an approved NDA with listed patents, but that is not the standard route for ordinary monograph-based OTC competition.

What patent litigation and settlement agreements affect the market?

No major active U.S. patent litigation or settlement regime is central to the ordinary loperamide hydrochloride-simethicone market. The relevant legal risks are more likely to involve:

• Trade dress and trademark disputes.
• False or misleading comparative advertising.
• Labeling and promotional claims.
• Product liability claims associated with misuse.
• Manufacturing defects or contamination.
• Private contractual disputes between brand owners, distributors, and suppliers.

The absence of core patent litigation increases the attractiveness of private-label and contract-manufacturing strategies. It also reduces the value of acquiring a narrow formulation patent unless the patent provides a clear manufacturing or market-access advantage.

How strong is the patent estate for loperamide-simethicone products?

The estate is weak at the active-ingredient level and potentially moderate at the formulation level.

Patent layer	Strength	Commercial assessment
Loperamide composition of matter	Very low	Long expired
Simethicone composition of matter	Very low	Mature ingredient
Broad combination claim	Low	Vulnerable to prior art and design-around
Specific excipient composition	Low to moderate	Depends on claim breadth and validity
ODT or chewable technology	Moderate in narrow use cases	May support differentiation
Packaging or dosing system	Low to moderate	Useful for brand defense, limited blocking power
Manufacturing process	Moderate if difficult to replicate	Can protect yield or quality advantages

A new patent program should focus on measurable technical benefits: improved content uniformity, faster disintegration, reduced simethicone segregation, improved taste, lower friability, or enhanced humidity stability. Broad claims that merely combine two known OTC actives are unlikely to provide durable protection.

What manufacturing and intellectual-property barriers exist?

The principal manufacturing barrier is achieving consistent distribution of simethicone and low-dose loperamide in a scalable process. Key process-development variables include particle size, order of addition, premixing, lubrication time, blend segregation, compression force, and coating conditions.

Potentially protectable know-how includes:

• A controlled premix of loperamide with a high-surface-area carrier.
• A simethicone adsorbate with improved flow.
• A low-moisture dry-granulation process.
• A coating system that minimizes tack and improves swallowability.
• A packaging configuration that preserves stability in humid climates.
• In-process controls for content uniformity and tablet weight.

Trade secrets may provide more practical value than patents if the process advantage is difficult to detect from the finished product.

How does the combination compare with single-ingredient products?

Product type	Consumer need	Commercial advantage	Limitation
Loperamide alone	Diarrhea control	Lower tablet cost and simple positioning	Does not address gas symptoms
Simethicone alone	Gas relief	Broad consumer familiarity	Does not control diarrhea
Combination product	Diarrhea plus gas discomfort	One-product convenience and broader symptom coverage	Larger tablet and more complex formulation
Bismuth products	Diarrhea and gastrointestinal discomfort	Multiple symptom claims	Different contraindications, taste, and staining concerns

The combination supports premium pricing over either single ingredient if the consumer perceives meaningful convenience. That premium is vulnerable to store-brand substitution because the underlying active ingredients are inexpensive and well known.

What licensing deals and commercial arrangements are relevant?

The most realistic commercial structures are:

1. Contract manufacturing for retailer brands.
2. Regional licensing of an established consumer-health trademark.
3. Technology licensing for chewable, ODT, or taste-masked platforms.
4. Distribution agreements for non-U.S. markets.
5. Co-development arrangements for pediatric-appropriate or senior-friendly formats, subject to labeling restrictions.

No major current licensing transaction is required to commercialize a conventional product. A licensing deal becomes more defensible when it includes a recognized brand, proprietary delivery technology, established retail access, or regulatory registrations in multiple jurisdictions.

What geographic opportunities exist?

The United States offers a large and established OTC market but has intense price competition. Europe and other jurisdictions may classify loperamide products differently, impose country-specific pack-size limits, or use pharmacy-controlled distribution. Simethicone combination products may have different labeling and permitted claims outside the United States.

Priority markets should be screened for:

• OTC versus pharmacy-only classification.
• Maximum loperamide dose and pack size.
• Pediatric labeling restrictions.
• Permitted simethicone claims.
• Local language and warning requirements.
• Import and manufacturing requirements.
• Reimbursement or pharmacy substitution rules.
• Existing trademark conflicts.

A single global formulation may not be optimal. Regional excipient choices may be needed to address humidity, excipient availability, color restrictions, flavor preferences, and local packaging standards.

What generic launch scenarios are most commercially credible?

Low-cost caplet launch

This is the highest-probability scenario. The product uses a standard immediate-release caplet, conventional excipients, blister or bottle packaging, and private-label or generic branding. Success depends on cost, supply reliability, and retailer access.

Premium swallowability launch

A coated caplet, mini-tablet, or ODT targets older consumers and consumers with swallowing difficulty. The product can command a higher price but requires stronger evidence of acceptable disintegration, mouthfeel, and stability.

Chewable flavored launch

This strategy emphasizes convenience and portability. It has higher formulation and sensory risk but can create product differentiation that is harder for a commodity caplet to match.

International localized launch

A regional product can use country-specific pack sizes, claims, and distribution channels. This approach may avoid direct competition with the strongest U.S. brands but requires multiple regulatory and supply-chain workstreams.

What is the revenue exposure and market outlook?

Public-company filings generally report broader consumer-health or self-care segments rather than product-level revenue for loperamide hydrochloride-simethicone combinations. Product-specific revenue should therefore be modeled from unit volume, average selling price, retailer margin, channel mix, and geographic reach rather than inferred from corporate segment totals.

The category has stable demand because diarrhea and gas are common acute symptoms. Growth is more likely to come from share transfer, private-label penetration, premium dosage forms, and international expansion than from new medical demand. Margin pressure is likely for conventional caplets because multiple suppliers can use broadly available active ingredients and standard excipients.

Key Takeaways

• Loperamide hydrochloride 2 mg plus simethicone 125 mg is a mature OTC combination with no meaningful active-ingredient exclusivity.
• The strongest commercial platform is a conventional immediate-release caplet.
• Excipient strategy should prioritize content uniformity, simethicone dispersion, rapid disintegration, low friability, and manufacturing yield.
• Chewable and orally disintegrating products offer differentiation but carry higher sensory, stability, and scale-up risk.
• The U.S. market is primarily a monograph, labeling, manufacturing, trademark, and distribution opportunity rather than an Orange Book patent opportunity.
• Paragraph IV litigation is not the normal entry mechanism for a conventional monograph-based OTC product.
• Formulation patents may be useful when tied to measurable technical performance, but broad combination claims are weak.
• Private-label supply, contract manufacturing, and regional licensing are the most credible commercial structures.
• Manufacturing know-how may provide more practical protection than a narrow excipient patent.
• Generic entry risk is high because the active ingredients are inexpensive, established, and widely available.

FAQs

Can loperamide and simethicone be formulated in a single tablet?

Yes. The marketed combination demonstrates commercial feasibility. The principal technical requirements are uniform distribution of simethicone, accurate dosing of the low-dose loperamide component, acceptable tablet strength, and rapid disintegration.

Are sugar-free loperamide-simethicone products commercially viable?

Yes, particularly in chewable formats. Mannitol, xylitol, or other sugar-free excipient systems can support the product, but hygroscopicity, taste, cooling effect, and gastrointestinal tolerability require control.

Can a new excipient create patent protection for this combination?

Potentially, but protection depends on unexpected technical performance and claim scope. A conventional substitution of one filler or disintegrant for another is less likely to produce durable patent value than a demonstrated improvement in stability, uniformity, taste, or disintegration.

Is simethicone absorbed systemically?

Simethicone is generally regarded as non-systemically absorbed when administered orally. Its commercial role is local action within the gastrointestinal tract, although product safety and labeling must follow the applicable FDA requirements. [1]

What is the best packaging for loperamide-simethicone caplets?

Blister packaging provides unit-dose control, portability, and tamper evidence. Bottles can reduce packaging cost and simplify high-volume retail supply. Humidity-sensitive chewable or ODT products may require higher-barrier blister materials or desiccant-controlled bottles.

References

1. U.S. Food and Drug Administration. (n.d.). DailyMed: Loperamide hydrochloride and simethicone tablet labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Patent and Trademark Office. (1973). U.S. Patent No. 3,714,159: 4-(p-chlorophenyl)-4-hydroxy-N,N-dimethyl-alpha,alpha-diphenyl-1-piperidinebutyramide. https://patents.google.com/

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book